Voranigo, the first new malignant brain tumor drug introduced in 20 years, has received an orphan drug designation in Korea.

The Ministry of Food and Drug Safety announced so through an official orphan drug designation notice on the 3rd.

Specifically, the drug is for the treatment of IDH-mutated diffuse glioma. Voranigo can be used to treat patients with low-grade glioma who are susceptible to isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) mutation.

Voranigo (vorasidenib) is an IDH1/2 dual inhibitor class drug developed by the multinational pharmaceutical giant Servier that targets a difficult-to-treat brain tumor, gliomas (including oligodendrog